PMID- 24999605
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20151119
IS  - 1473-5709 (Electronic)
IS  - 0959-8278 (Linking)
VI  - 23
IP  - 5
DP  - 2014 Sep
TI  - MMP3 and CXCL1 are potent stromal protein markers of dysplasia-carcinoma 
      transition in sporadic colorectal cancer.
PG  - 336-43
LID - 10.1097/CEJ.0000000000000058 [doi]
AB  - Early molecular detection of the colorectal dysplasia-carcinoma transition may 
      augment the accuracy of diagnosis in case of biopsy orientation errors. The 
      combination of high-throughput microarray-based biomarker screening with tissue 
      microarray-based prospective protein biomarker expression analysis could 
      represent an additional test in routine automated diagnostic procedures. Our aim 
      was to test and select protein markers to identify protein expression profile 
      alterations, focusing on the dysplasia-carcinoma transition in sporadic 
      colorectal tumors. Dysplasia-carcinoma transition-specific transcript sets were 
      previously identified using HGU133plus2 microarrays and Taqman RT-PCR cards. 
      Here, 26 potential dysplasia-carcinoma transition-specific markers were tested by 
      immunohistochemistry at the protein level using tissue microarrays in a total of 
      168 independent colonic biopsy samples. A set of 26 transcripts [including matrix 
      metalloproteinase-3 (MMP3) and chemokine (C-X-C motif) ligand 1 (CXCL1)] has been 
      determined recently, indicating a linear expression correlation with the 
      adenoma-dysplasia-carcinoma sequence, thereby having the potential to 
      discriminate between dysplasia and early malignancy. Currently, we find that 
      high-grade dysplastic sessile adenomatous-stage and early-stage colorectal cancer 
      conditions can be differentiated correctly by the stromal expression of MMP3 and 
      CXCL1, respectively, on tissue microarray-based analysis. Furthermore, in cases 
      of sporadic colorectal tumors, MMP3 protein expression in the lamina propria 
      itself seems to be highly specific for the detection of tumorous transition. Our 
      current and recent results indicate that appropriate antibody marker combinations 
      are highly suitable for tissue microarray-based and digital microscopy-based, 
      automated, high-capacity diagnostic application in tumorous colonic diseases.
FAU - Sipos, Ferenc
AU  - Sipos F
AD  - a2nd Department of Internal Medicine bFaculty of Medicine, Department of Medicine 
      c1st Department of Pathology and Experimental Cancer Research, Semmelweis 
      University dMolecular Medicine Research Unit, Hungarian Academy of Sciences, 
      Budapest, Hungary.
FAU - Germann, Tiana M
AU  - Germann TM
FAU - Wichmann, Barnabas
AU  - Wichmann B
FAU - Galamb, Orsolya
AU  - Galamb O
FAU - Spisak, Sandor
AU  - Spisak S
FAU - Krenacs, Tibor
AU  - Krenacs T
FAU - Tulassay, Zsolt
AU  - Tulassay Z
FAU - Molnar, Bela
AU  - Molnar B
FAU - Muzes, Gyorgyi
AU  - Muzes G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Cancer Prev
JT  - European journal of cancer prevention : the official journal of the European 
      Cancer Prevention Organisation (ECP)
JID - 9300837
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CXCL1 protein, human)
RN  - 0 (Chemokine CXCL1)
RN  - 0 (RNA, Messenger)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adenoma/*diagnosis/genetics/metabolism
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Carcinoma, Transitional Cell/*diagnosis/genetics/metabolism
MH  - Chemokine CXCL1/genetics/*metabolism
MH  - Colon/metabolism/*pathology
MH  - Colorectal Neoplasms/*diagnosis/genetics/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Profiling
MH  - Humans
MH  - Hyperplasia/*diagnosis/genetics/metabolism
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Matrix Metalloproteinase 3/genetics/*metabolism
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stromal Cells/metabolism/*pathology
MH  - Tissue Array Analysis
EDAT- 2014/07/08 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/07/08 06:00
PHST- 2014/07/08 06:00 [entrez]
PHST- 2014/07/08 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - 10.1097/CEJ.0000000000000058 [doi]
PST - ppublish
SO  - Eur J Cancer Prev. 2014 Sep;23(5):336-43. doi: 10.1097/CEJ.0000000000000058.